Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Telaglenastat (CB-839) + COMETRIQ (Cabozantinib) - (CANTATA) | Renal cell carcinoma | Phase 2 | Trial Discontinued | Oral | Oncology |
| Talphera Inc. | Zalviso | Post-operative pain following open abdominal surgery and hip or knee replacement surgery | Phase 3 | Sublingual | Non-Opioid Analgesic | |
| Talphera Inc. | Nafamostat - (NEPHRO CRRT) | Continuous renal replacement therapy (CRRT) | Phase 3 | Ongoing | Intravenous | N/A |
| Tarsus Pharmaceuticals Inc. | TP-03 - (Saturn-1) | Demodex Blepharitis | Phase 2/3 | Trial Completed | Topical | Opthalmic |
| Tarsus Pharmaceuticals Inc. | TP-04 - (Galatea) | Rosacea | Phase 2 | Data Released | topical | N/A |
| Tarsus Pharmaceuticals Inc. | TP-03 - (ERSA) | Meibomian Gland Disease in patents with Demodex mites | Phase 2a | Data Released | topical | Opthalmic |
| Tarsus Pharmaceuticals Inc. | TP-05 - (Carpo) | Lyme disease | Phase 2a | Data Released | Oral | Antibiotic |
| TC BioPharm (Holdings) plc | OmnImmune (TCB008) - (ACHIEVE) | Acute Myeloid Leukemia | Phase 2b | Data Released | Intravenous | Oncology |
